NCT05421104View on ClinicalTrials.gov

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

CompletedOBSERVATIONAL
Enrollment

1,576

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
Polycythemia Vera (PV)
Interventions
OTHER

Ruxolitinib

PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.

Trial Locations (1)

07936-1080

Novartis Investigative Site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY